Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHA2 | P29317 | 4/20 | 0.54 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.51 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.51 |
| ▸ | DRD4 | P21917 | 15/20 | 0.46 |
| ▸ | DRD2 | P14416 | 1/20 | 0.46 |
| ▸ | RBP4 | P02753 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4301622 | 1.00 | EPHA2 (0.54) | EPHA2ERBB2EPHB4DRD4DRD2 | |
| SCHEMBL29827125 | 0.85 | EPHA2 (0.51) | EPHA2ERBB2EPHB4 | |
| SCHEMBL4510923 | 0.82 | EPHA2 (0.54) | EPHA2ERBB2EPHB4DRD4 | |
| SCHEMBL304726 | 0.80 | KDM4E (0.51) | EPHA2ERBB2EPHB4DRD4DRD2 | |
| SCHEMBL304725 | 0.80 | KDM4E (0.51) | EPHA2ERBB2EPHB4DRD4DRD2 | |
| SCHEMBL28851224 | 0.79 | EPHA2 (0.51) | EPHA2ERBB2EPHB4DRD4 | |
| SCHEMBL1700442 | 0.79 | EPHA2 (0.51) | EPHA2ERBB2EPHB4 | |
| SCHEMBL306369 | 0.79 | EPHA2 (0.50) | EPHA2ERBB2EPHB4DRD4 | |
| SCHEMBL22944175 | 0.79 | EPHA2 (0.52) | EPHA2ERBB2EPHB4 | |
| SCHEMBL4302361 | 0.79 | DRD4 (0.54) | EPHA2EPHB4DRD4DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090312288-A1 | KINASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-12-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090312288-A1 | KINASE INHIBITORS | MAP3K20, MAP3K1, MAP3K19 | EPHA2 950/4885ERBB2 85/4885EPHB4 1910/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.